Relay Therapeutics Inc
RLAYHealthcare|Biotechnology|USA
$20.00
-0.74 (-3.59%)
Tangible Book
$3.39
Earnings Power
$3247.43
About
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Stock Price
+436.2%(1Y)
Pipeline Summary
7 total trials3
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 4Completed: 2Terminated: 1
Active Trials (4)
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS)
Phase 2Recruiting
Enrollment: 277 participants
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma
Phase 1Recruiting
Enrollment: 35 participants
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation
Phase 3Recruiting
Enrollment: 540 participants
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432PIK3CA Mutation
Phase 1Recruiting
Enrollment: 930 participants
BioScore
4.9/10
Cautious
Ownership
Recent Insider Trades
Patel SanjivSELL
2026-07-0748,199 shares @ $19.58
Bergstrom Donald ASELL
2026-07-068,660 shares @ $18.71
Catinazzo ThomasSELL
2026-07-0617,717 shares @ $18.69
Rahmer PeterSELL
2026-06-3050,000 shares @ $19.09
Catinazzo ThomasSELL
2026-06-22187,163 shares @ $16.97
Recent News
2026-07-09 00:03:39
2026-07-08 14:51:24
2026-07-02 22:08:49
Data last updated: Jul 12, 2026, 07:37 PM